What the FDA labels say about taking them together
Atovaquone and quizartinib
Quizartinib's FDA label of April 16, 2026 names atovaquone in its drug interactions section; the atovaquone label PlainMeds reads does not name quizartinib. The quizartinib label: “… ondansetron, granisetron, azithromycin, pentamidine, doxycycline, moxifloxacin, atovaquone, prochlorperazine, and tacrolimus.”
Check it at the source: the atovaquone FDA label on DailyMed (effective March 20, 2026); the quizartinib FDA label on DailyMed (effective April 16, 2026, Daiichi Sankyo Inc.).
What does the atovaquone label say about quizartinib?
Atovaquone's label (effective March 20, 2026) does not name quizartinib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (MEPRON), GlaxoSmithKline LLC, effective March 20, 2026 (SPL set b426b6bf-f07e-4580-97ae-dfca1ddf5b8f), via openFDA; the full label on DailyMed
What does the quizartinib label say about atovaquone?
Quizartinib label, drug interactionsQT Interval Prolonging Drugs Clinical Impact VANFLYTA prolongs the QT/QTc interval. Coadministration of VANFLYTA with other drugs that prolong the QT interval may further increase the incidence of QT prolongation [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.2) ]. Prevention or Management Monitor patients more frequently with ECG if co-administration of VANFLYTA with drugs known to prolong the QT interval is required. Examples of QT prolonging drugs include but are not limited to antifungal azoles, ondansetron, granisetron, azithromycin, pentamidine, doxycycline, moxifloxacin, atovaquone, prochlorperazine, and tacrolimus.
Source: FDA drug label (VANFLYTA), Daiichi Sankyo Inc., effective April 16, 2026 (SPL set 29cdbcfe-497d-4e78-bb7b-2d4acafe8e86), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atovaquone | Quizartinib | |
|---|---|---|
| Labeled for | n/a | Leukemia, lymphoma and myeloma |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.767 per mL 750 mg/5 mL suspension | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once